Response to a Differing Perspective

Response to Perspective

Cooper questions one specific technical aspect of our study - the site of cleavage in EIN2 - and suggests that cleavage of EIN2 likely occurs elsewhere. Here, we explain how our immunoblotting, mass spectrometry and genetic mutation studies justify our conclusions.

Yet another perspective: a response to Connolly

Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects

Treatment-resistance in schizophrenia remains a public health problem: about 20% to 30% of patients do not respond to antipsychotic therapy. Clozapine has been shown to be effective in about one-third of patients, but the medical risks and weekly blood tests limit its broad application. While the heterogeneity of the disease and the duration of untreated psychosis are important, pharmacogenomic...

Differing views on views: response to Hayward and Tarr (2000)

At the outset we should emphasize that nothing in Hayward and Tarr’s commentary speaks to the main results of the Biederman and Bar (1999) report: Slight costs of rotation in detecting geon differences when matching a sequential pair of novel objects (3.3% increase in error rates), but massive costs (46.2% increase in error rates) in the detection of metric differences. Their comments are all a...

Response to Bell: industry perspective.

D avid S.H. Bell’s letter in the March issue of Diabetes Care (1) raises important and timely concerns about the ethics of conducting placebo controlled trials for regulatory approval of compounds for the treatment of type 2 diabetes. Standard pivotal trial design involves withdrawal of patients from current therapy and comparison of the investigational drug with an inactive placebo rather than...